This study aimed to examine the effect of physical activity (PA) on health through changes in multi-omics biomarkers during 6 months of exercise intervention.
This study aimed to examine the effect of physical activity (PA) on health through changes in multi-omics biomarkers during 6 months of exercise intervention. Twenty-seven healthy middle-aged women were recruited and 14 subjects completed the exercise intervention. A total of three blood and stool samples were collected at 3-month intervals. The amount of PA was measured with an accelerometer. Clinical variables were used, including blood pressure, grip strength, flexibility, and blood glucose levels and lipid markers obtained from laboratory tests. The concentration of blood metabolites was measured by targeted metabolomics. Fecal microbiome data were obtained by 16S rRNA gene amplicon sequencing. During the second half period (period 2), Coronavirus disease 2019 (COVID-19) occurred and spread out in Korea, and PA decreased compared with the first half period (period 1). Blood pressure, hemoglobin A1c (HbA1c), and low-density lipoprotein cholesterol (LDL-C) decreased in period 1 and tended to increase again during period 2. Forty metabolites were changed significantly during period 1, and investigators found that 6 of them were correlated with changes in blood pressure, HbA1c, and LDL-C via network analysis. Our results may suggest the relationship between changes in biomarkers at multi-omics levels during exercise and a message that reduced PA due to COVID-19 can adversely affect health.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
27
The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises. During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements.
Seoul National University
Seoul, South Korea
Change in Systolic blood pressure (SBP) between baseline and 3rd month
blood pressure (mmHg) (Omron Corporation, Kyoto, Japan)
Time frame: baseline ~ 3 month
Change in Systolic blood pressure (SBP) between 3rd month and 6th month
blood pressure (mmHg) (Omron Corporation, Kyoto, Japan)
Time frame: 3 ~ 6 month
Changes in diastolic blood pressure (DBP) between baseline and 3rd month
blood pressure (mmHg) (Omron Corporation, Kyoto, Japan)
Time frame: baseline ~ 3 month
Changes in diastolic blood pressure (DBP) between 3rd month and 6th month
blood pressure (mmHg) (Omron Corporation, Kyoto, Japan)
Time frame: 3 ~ 6 month
Changes in hemoglobin A1c (HbA1c) between baseline and 3rd month
The concentrations of hemoglobin A1c (HbA1c) (mg/dL) (HLC-723G11 analyzer, TOSOH kabushiki kaisha, HPLC)
Time frame: baseline ~ 3 month
Changes in hemoglobin A1c (HbA1c) between 3rd month and 6th month
The concentrations of hemoglobin A1c (HbA1c) (mg/dL) (HLC-723G11 analyzer, TOSOH kabushiki kaisha, HPLC)
Time frame: 3 ~ 6 month
Changes in total cholesterol between baseline and 3rd month
total cholesterol (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
Time frame: baseline ~ 3 month
Changes in total cholesterol between 3rd month and 6th month
total cholesterol (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 3 ~ 6 month
Changes in high-density lipoprotein cholesterol (HDL-C) between baseline and 3rd month
high-density lipoprotein cholesterol (HDL-C) (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
Time frame: baseline ~ 3 month
Changes in high-density lipoprotein cholesterol (HDL-C) between 3rd month and 6th month
high-density lipoprotein cholesterol (HDL-C) (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
Time frame: 3 ~ 6 month
Changes in low-density lipoprotein cholesterol (LDL-C) betweenbaseline and 3rd month
low-density lipoprotein cholesterol (LDL-C) (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
Time frame: baseline ~ 3 month
Changes in low-density lipoprotein cholesterol (LDL-C) between 3rd month and 6th month
low-density lipoprotein cholesterol (LDL-C) (mg/dL) (Cobas C701/702 autochemistry analyzer, Roche, enzyme method)
Time frame: 3 ~ 6 month
Changes in Microbiome between baseline and 3rd month
The composition of the gut microbiome obtained by 16S rRNA gene amplicon sequencing.
Time frame: baseline ~ 3 month
Changes in Microbiome between 3rd month and 6th month
The composition of the gut microbiome obtained by 16S rRNA gene amplicon sequencing.
Time frame: 3 ~ 6 month
Changes in Metabolome between baseline and 3rd month
Plasma metabolite concentrations were measured by using the AbsoluteIDQ p 180 kit and the Bile acids kit.
Time frame: baseline ~ 3 month
Changes in Metabolome between 3rd month and 6th month
Plasma metabolite concentrations were measured by using the AbsoluteIDQ p 180 kit and the Bile acids kit.
Time frame: 3 ~ 6 month